Adjuvant Pembrolizumab Cuts Recurrence in Stage II Melanoma
Compared with placebo, pembrolizumab prolonged regression-free survival in resected high-risk stage IIB and IIC melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.